title: A novel peptide to disrupt the interaction of BST-2 and Vpu.
abstract: Bone marrow stromal cell antigen 2 (BST-2) inhibits the release of HIV-1 and other enveloped viruses from the cell surface. HIV-1 Vpu binds to BST-2 through an interaction between transmembrane domains (TMD) of the two proteins and induces the downregulation of cell surface BST-2, thereby counteracting its antiviral activity. In this study, we designed and prepared a modified peptide BST2-TM-P1, which include the sequence of BST-2 TMD, keeping its property competing with BST-2 to bind with Vpu. Biological assay results indicate BST2-TM-P1 could increase the BST-2 level at the cell surface in Vpu dependent manner and significantly inhibit the replication of HIV-1 virion. Our studies indicate that blocking the interaction of Vpu and BST-2 is an effective way to combat HIV-1 infection.
authors.affiliation: Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China.
authors.forename: Zeyun
authors.initials: Z
authors.lastname: Mi
authors.forename: Xin
authors.initials: X
authors.lastname: Wang
authors.forename: Yang
authors.initials: Y
authors.lastname: He
authors.forename: Xiaoyu
authors.initials: X
authors.lastname: Li
authors.forename: Jiwei
authors.initials: J
authors.lastname: Ding
authors.forename: Hongyun
authors.initials: H
authors.lastname: Liu
authors.forename: Jinming
authors.initials: J
authors.lastname: Zhou
authors.forename: Shan
authors.initials: S
authors.lastname: Cen
mesh_terms: D000595:Amino Acid Sequence; D015703:Antigens, CD / Q000378:metabolism*; D001681:Biological Assay; D002462:Cell Membrane / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology; D006367:HeLa Cells; D054298:Human Immunodeficiency Virus Proteins / Q000378:metabolism*; D006801:Humans; D008562:Membrane Glycoproteins / Q000378:metabolism; D008958:Models, Molecular; D008969:Molecular Sequence Data; D010455:Peptides / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D011485:Protein Binding / Q000187:drug effects; D017434:Protein Structure, Tertiary; D058525:Quartz Crystal Microbalance Techniques; D060327:Solid-Phase Synthesis Techniques; D014721:Vesicular stomatitis Indiana virus / Q000378:metabolism; D014759:Viral Envelope Proteins / Q000378:metabolism; D054334:Viral Regulatory and Accessory Proteins / Q000378:metabolism*; D014779:Virus Replication / Q000187:drug effects; D000086082:Viroporin Proteins
chemical_list: D015703:Antigens, CD; D054298:Human Immunodeficiency Virus Proteins; D008562:Membrane Glycoproteins; D010455:Peptides; D014759:Viral Envelope Proteins; D054334:Viral Regulatory and Accessory Proteins; C028391:G protein, vesicular stomatitis virus; C514859:vpu protein, Human immunodeficiency virus 1; D000086082:Viroporin Proteins
keywords: Vpu; anti-HIV-1; bone marrow stromal cell antigen 2; drug design